Compare BioNano Genomics Inc (BNGO) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Manulife Financial Corporation — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while Manulife Financial Corporation trades at $44.03 (market cap $72.68B). The key difference: Manulife Financial Corporation is far larger — about 5320.6× BioNano Genomics Inc's market cap, and Manulife Financial Corporation pays a 3.1% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MFC | |
|---|---|---|
Market Cap | $13.66M | $72.68B |
Sector | Health | Financials |
52-Week High | $4.92 | $44.77 |
52-Week Low | $1.06 | $30.06 |
Enterprise Value | $16.26M | $67.84B |
Dividend Yield | — | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Manulife Financial (MFC) trades at $44.15, down 0.38% on the day, with a bullish technical signal from moving averages and neutral oscillators. Revenue grew to $53.01B in 2025, with net income of $5.78B, and the company has a strong analyst consensus of 57% buy ratings. Recent Q2 2026 earnings beat expectations, driven by Asia growth and insurance sales, while dividends of $0.49 per share were declared for H1 and H2 2026.
MFC's outlook is positive due to earnings momentum and strategic AI partnerships, but risks include premium valuation and segment volatility. The stock offers steady dividends and growth potential, though investors should monitor execution in wealth management and macroeconomic impacts on insurance demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
